Scientists are increasingly learning that Alzheimer’s disease begins many years before memory problems become obvious.
During this early period, harmful changes slowly build up inside the brain. Finding treatments that can stop these changes early may offer the best chance of slowing the disease.
Researchers at King’s College London have reported encouraging results for an experimental medicine called KCL-286.
Instead of targeting only one feature of Alzheimer’s disease, the drug appears to affect several important biological processes at the same time. The research was carried out in mice and offers a new direction for future studies.
The study focused on problems that appear very early in Alzheimer’s disease. Along with the well-known amyloid-beta and tau proteins, scientists are now paying more attention to inflammation and damage to DNA. These changes may help trigger the disease long before serious memory loss develops.
KCL-286 reduced inflammation and repaired damaged DNA in the brains of mice with Alzheimer’s disease. According to the researchers, this combination could make the drug a disease-modifying treatment, meaning it may slow the disease itself instead of simply easing symptoms.
One advantage of KCL-286 is that it is taken by mouth as a tablet rather than by injection. The drug was originally created to treat spinal cord injury and has already completed Phase 1 safety and tolerability testing in people. Because these early safety studies are already finished, future Alzheimer’s research may progress more quickly.
The medicine works by activating part of the retinoic acid pathway, which is involved in the body’s use of vitamin A. Earlier research suggested this pathway is connected to the formation of amyloid plaques. The new study showed that activating it may also improve the repair of serious DNA damage inside brain cells.
The researchers compared DNA double-strand breaks to a rope snapping completely in two. These severe breaks can interfere with the normal function of brain cells if they are not repaired. KCL-286 appeared to help the cells fix this damage more effectively.
The idea for studying the drug came from earlier work showing that spinal cord injury and Alzheimer’s disease share some of the same biological pathways. Since KCL-286 had already shown promise in protecting nerve cells after injury, the team wanted to see whether it could also protect brain cells in Alzheimer’s disease.
The study adds to growing evidence that future Alzheimer’s treatments may need to attack several disease processes at once. Targeting only amyloid or tau may not be enough because inflammation, DNA damage, and other changes all seem to contribute to the illness.
Although the results are promising, this research is still at an early stage because it was performed in animals. Human clinical trials will be needed to find out whether patients receive the same benefits.
The fact that the medicine has already passed Phase 1 safety testing is an important strength because it could shorten development time. Overall, the findings suggest KCL-286 deserves further study as a possible new treatment for Alzheimer’s disease.
If you care about Alzheimer’s disease, please read studies about the protective power of dietary antioxidants against Alzheimer’s, and eating habits linked to higher Alzheimer’s risk.
For more health information, please see recent studies that oral cannabis extract may help reduce Alzheimer’s symptoms, and Vitamin E may help prevent Parkinson’s disease.
